文献速递冠心病心力衰竭与心肌病

经皮微轴左心室辅助装置与主动脉内球囊反搏或无机械循环支持在心源性休克患者中的比较效果

Comparative Effectiveness of Percutaneous Microaxial Left Ventricular Assist Device vs Intra-Aortic Balloon Pump or No Mechanical Circulatory Support in Patients With Cardiogenic Shock.
PubMed 文献 · JAMA Cardiol · 2023-01-01

在逆概率治疗加权分析和宽限期方法中,经皮微轴左心室辅助装置与更高的风险调整30天死亡率相关(风险差异14.9%;95%CI 12.9%-17.0%)。工具变量分析也显示30天死亡率更高(风险差异13.5%;95%CI 3.9%-23.2%),但工具化双重差分分析中关联不精确,且各分析均提示可能存在未测量混杂,违反关键假设。

要点

  • 在部分观察性分析中,经皮微轴左心室辅助装置与急性心肌梗死合并心源性休克患者更高的30天死亡率相关。
  • 工具化双重差分分析中关联不精确,无法得出有意义的结论。
  • 各分析均提示治疗组间患者和机构特征分布差异可能导致未测量混杂,违反因果推断关键假设。

核心结论

  • 在急性心肌梗死合并心源性休克的观察性分析中,经皮微轴左心室辅助装置在部分分析中与更差结局相关,而在其他分析中关联不精确,无法得出有意义的结论。
  • 患者和机构特征分布差异及未捕获的疾病严重程度因素提示违反关键假设,需随机临床试验来有效比较候选治疗策略。

研究设计与样本

  • 采用逆概率治疗加权、工具变量分析、工具化双重差分分析和宽限期方法比较经皮微轴左心室辅助装置与替代治疗(包括药物治疗和主动脉内球囊反搏)。
  • 主要结局为30天全因死亡率和再入院率。

主要发现

  • 逆概率治疗加权分析和宽限期方法中,经皮微轴左心室辅助装置与更高的风险调整30天死亡率相关(风险差异14.9%;95%CI 12.9%-17.0%)。
  • 接受经皮微轴左心室辅助装置的患者有更高频率的严重疾病相关因素,提示可能存在未测量疾病严重程度混杂。
  • 工具变量分析中,经皮微轴左心室辅助装置的30天死亡率也更高(风险差异13.5%;95%CI 3.9%-23.2%),但患者和医院特征在工具变量水平间存在差异,提示可能未测量变量混杂。
  • 工具化双重差分分析中,经皮微轴左心室辅助装置与死亡率的关联不精确,且不同使用模式的医院间特征趋势差异提示潜在假设违反。

临床怎么用

  • 临床医生在考虑对急性心肌梗死合并心源性休克患者使用经皮微轴左心室辅助装置时,应知晓观察性数据显示其与更高30天死亡率相关,但存在未测量混杂可能。
  • 需等待随机临床试验结果以指导机械支持装置的选择。

局限性

  • 观察性分析可能受未测量疾病严重程度因素混杂,数据中缺乏相关指标。
  • 工具变量分析中患者和医院特征在工具变量水平间存在差异,提示可能未测量混杂。
  • 工具化双重差分分析中关联不精确,且医院间特征趋势差异提示潜在假设违反。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Recent studies have produced inconsistent findings regarding the outcomes of the percutaneous microaxial left ventricular assist device (LVAD) during acute myocardial infarction with cardiogenic shock (AMICS). OBJECTIVE: To compare the percutaneous microaxial LVAD vs alternative treatments among patients presenting with AMICS using observational analyses of administrative data. DESIGN, SETTING, AND PARTICIPANTS: This comparative effectiveness research study used Medicare fee-for-service claims of patients admitted with AMICS undergoing percutaneous coronary intervention from October 1, 2015, through December 31, 2019. Treatment strategies were compared using (1) inverse probability of treatment weighting to estimate the effect of different baseline treatments in the overall population; (2) instrumental variable analysis to determine the effectiveness of the percutaneous microaxial LVAD among patients whose treatment was influenced by cross-sectional institutional practice patterns; (3) an instrumented difference-in-differences analysis to determine the effectiveness of treatment among patients whose treatment was influenced by longitudinal changes in institutional practice patterns; and (4) a grace period approach to determine the effectiveness of initiating the percutaneous microaxial LVAD within 2 days of percutaneous coronary intervention. Analysis took place between March 2021 and December 2022. INTERVENTIONS: Percutaneous microaxial LVAD vs alternative treatments (including medical therapy and intra-aortic balloon pump). MAIN OUTCOMES AND MEASURES: Thirty-day all-cause mortality and readmissions. RESULTS: Of 23 478 patients, 14 264 (60.8%) were male and the mean (SD) age was 73.9 (9.8) years. In the inverse probability of treatment weighting analysis and grace period approaches, treatment with percutaneous microaxial LVAD was associated with a higher risk-adjusted 30-day mortality (risk difference, 14.9%; 95% CI, 12.9%-17.0%). However, patients receiving the percutaneous microaxial LVAD had a higher frequency of factors associated with severe illness, suggesting possible confounding by measures of illness severity not available in the data. In the instrumental variable analysis, 30-day mortality was also higher with percutaneous microaxial LVAD, but patient and hospital characteristics differed across levels of the instrumental variable, suggesting possible confounding by unmeasured variables (risk difference, 13.5%; 95% CI, 3.9%-23.2%). In the instrumented difference-in-differences analysis, the association between the percutaneous microaxial LVAD and mortality was imprecise, and differences in trends in characteristics between hospitals with different percutaneous microaxial LVAD use suggested potential assumption violations. CONCLUSIONS: In observational analyses comparing the percutaneous microaxial LVAD to alternative treatments among patients with AMICS, the percutaneous microaxial LVAD was associated with worse outcomes in some analyses, while in other analyses, the association was too imprecise to draw meaningful conclusions. However, the distribution of patient and institutional characteristics between treatment groups or groups defined by institutional differences in treatment use, including changes in use over time, combined with clinical knowledge of illness severity factors not captured in the data, suggested violations of key assumptions that are needed for valid causal inference with different observational analyses. Randomized clinical trials of mechanical support devices will allow valid comparisons across candidate treatment strategies and help resolve ongoing controversies.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Almarzooq, Song, Dahabreh, et al. Comparative Effectiveness of Percutaneous Microaxial Left Ventricular Assist Device vs Intra-Aortic Balloon Pump or No Mechanical Circulatory Support in Patients With Cardiogenic Shock. JAMA Cardiol. 2023. PMID: 37342056. doi:10.1001/jamacardio.2023.1643

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。